Environmental

ARAY’s R&D intensity near 9.4% of revenue supports product efficiency and lower-resource innovation versus peers, but it is not clearly differentiated in medtech.

The company’s capital allocation appears balanced on disclosed metrics, yet the absence of direct emissions, energy, or waste disclosures limits evidence of environmental leadership versus peers.

Negative net debt to EBITDA suggests limited balance-sheet pressure, which can support longer-horizon environmental investments, but this is an indirect and non-ESG-specific advantage.

No material environmental controversies were provided, so the main relative constraint is disclosure depth rather than a demonstrated operational environmental disadvantage.

Social

ARAY’s low stock-based compensation at roughly 1.6% of revenue suggests restrained dilution and may align employee incentives more cleanly than higher-paying peers.

R&D spending near 9.4% of revenue indicates continued investment in product development, which can support patient and clinician outcomes relative to less innovative peers.

The provided data do not include workforce, safety, or product-quality metrics, so social positioning cannot be confirmed as stronger than peers on direct evidence.

Without disclosed controversy data, ARAY appears broadly neutral on social risk, but the limited transparency keeps its relative social score below stronger-disclosure peers.

Governance

ARAY’s debt-to-equity ratio of 4.41 indicates a leveraged capital structure, which can increase governance scrutiny versus peers with more conservative balance sheets.

Negative net debt to EBITDA suggests manageable near-term leverage serviceability, partially offsetting the governance concern from the high debt-to-equity reading.

Low stock-based compensation supports somewhat disciplined executive and employee compensation practices relative to peers with heavier equity dilution.

The absence of board, audit, and controversy disclosures in the provided data limits confidence, so governance is assessed as average rather than leading.

Overall Score

ARAY’s ESG positioning is broadly average versus peers, with modest strengths in disciplined compensation and innovation investment offset by limited disclosure depth and leverage-related governance concerns.

Score Driver: Limited ESG Disclosure Depth Relative To Peers